The fight against cancer is one of today's most urgent scientific tasks and of highest importance to public health. Despite a continuous improvement of the biomedical understanding of the genesis of cancer and the development of new therapeutic methods, every year 20.000 pepole are dying of cancer in Austria. Chemotherapy in all its forms is still the main therapy option for patients with metastasizing cancer, and metal-based drugs are an important part of the treatment of many types of cancer.

The Research-Platform Translational Cancer Therapy Research was founded in 2008 as a joint project of Bernhard Keppler from the Institute of Inorganic Chemistry, University of Vienna, and Walter Berger and Michael Micksche from the Institute of Cancer Research, Medical University of Vienna, and was renewed as an Inter-University Clusterproject in 2016. The aim of the project is the development of new metal-based tumourtherapeutics as well as a better understanding of their modes of action. This information in turn allows for a systematic improvement of anti-cancer drugs and their optimisation for future clinical trials.

The Research Cluster promotes the intensive multidiciplinary collaboration between chemists, cell biologists and molecular biologists necessary for major advances in the fight against cancer. So far, three first-in-class compounds based on titanium, gallium and ruthenium have reached clinical studies; the ruthenium compounds IT-139 (KP1339) and LX-001 (KP46) are currently under development in USA and Canada.


Aims  |  Team  |  Publications  |  News



New publication of the Luca Salassa Group together with members of the Cluster Translational Cancer Therapy Research in in Science Reports


Nadine S. Sommerfeld, Christian Kowol and Petra Heffeter have received a grant for the (pre)clinical development of the platinum compound "Albuplatin"


The project "Innovative Nanocarriers for Tumor-Specific Accumulation of Thiosemicarbazones" has been approved by the FWF decision board on Oct.1 2018.


Debora Wernitznig presented the latest findings on the mode of action of IT-139 at the Annual Meeting of the American Association of Cancer Research...


Bernhard Keppler talks with Hanna Möller (uni:view) about NanoSIMS, brain-drain, and the possibilities and limitations of cancer therapy.


Dr. Alessio Terenzi's INDICAR Fellowship has been extended for five months until April 2018.